The Catalyst® Cortisol Test provides veterinarians with real-time critical insights when evaluating dogs for Addison's disease and Cushing's syndromeWESTBROOK, Maine, June 5, 2025 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst® Cortisol Test, which measures real-time quantitative cortisol concentrations to support the diagnosis of Addison's disease and diagnosis and management of Cushing's syndrome in dogs. ID ...

Since I upgraded IDEXX Laboratories, Inc. (NASDAQ: IDXX ) to a Buy rating in March 2025, the stock price has increased by more than 22%. The company delivered a strong quarterly result despite a decline in U.S. clinical visits. I reiterateMore than 15 years of professional investment experience in global equities across all sectors. My investment style is fundamental, bottom-up, long-term, and quality growth-oriented. I am seeking companies specializing in niche markets, with strong growth potential, a soli ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Idexx Laboratories (IDXX) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Idexx Laboratories is one of 1001 individual stocks in the Medical sect ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ COMMISSION FILE NUMBER: 000-19271 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware ...

业绩总结 - IDEXX Q1 2025的总收入为9.98亿美元，同比增长4%[1] - CAG诊断的经常性收入为8.06亿美元，同比增长3%[1] - Q1的每股收益为2.96美元，同比增长5%[1] - IDEXX VetLab®消耗品的收入为3.45亿美元，同比增长9%[1] 未来展望 - 预计2025年总收入在40.95亿至42.10亿美元之间，报告增长为5%至8%[6] - 预计2025年每股收益在11.93至12.43美元之间，报告增长为-12%至17%[6] - 2025年CAG诊断经常性收入的有机增长预计为5%至8%[6] - 2025年运营利润率预计在31.1%至31.6%之间[7] - 2025年自由现金流预计在80%至85%之间[6] - 2025年资本支出约为1.6亿美元[6]

Idexx Laboratories (IDXX) came out with quarterly earnings of $2.96 per share, beating the Zacks Consensus Estimate of $2.92 per share. This compares to earnings of $2.81 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.37%. A quarter ago, it was expected that this Animal diagnostic and health care company would post earnings of $2.40 per share when it actually produced earnings of $2.62, delivering a surprise of 9.17%.Over t ...

IDEXX Laboratories (IDXX) Q1 2025 Earnings Call May 01, 2025 08:30 AM ET Company Participants Andrew Emerson - Executive VP, CFO and TreasurerJay Mazelsky - President and CEOMichael Ryskin - Managing DirectorKatarina Markovic - Executive DirectorJonathan Block - Managing DirectorDaniel Clark - VP - Equity Research Conference Call Participants Erin Wright - AnalystBrandon Vazquez - Research AnalystDavid Westenberg - Managing Director & Senior Research AnalystNavann Ty Dietschi - Lead Analyst Operator Good mo ...

IDEXX Laboratories (IDXX) Q1 2025 Earnings Call May 01, 2025 08:30 AM ET Speaker0 Good morning, and welcome to the IDEXX Laboratories First Quarter twenty twenty five Earnings Conference Call. As a reminder, today's conference is being recorded. Participating in the call this morning are Jay Mazelski, President and Chief Executive Officer Andrew Emerson, Chief Financial Officer and John Rebus, Vice President, Investor Relations. IDEXX would like to preface the discussion today with a caution regarding forwa ...

Exhibit 99.1 First Quarter Results FOR IMMEDIATE RELEASE Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces First Quarter Results WESTBROOK, Maine, May 1, 2025— IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. "IDEXX drove solid execution in the first quarter while advancing key enablers of our innovation-driven growth strategy. At the end of March, IDEXX launched a first-of-its-kind innovation, ID ...

Idexx Laboratories (IDXX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on May 1, 2025, might help the stock move higher if these key numbers are better than ...